Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine, a structure–activity relationship shared by the arylcyclohexylamines.
Safety at a Glance
High Risk- China: As of October 2015, methoxphenidine is a controlled substance in China.
- Italy: Methoxphenidine is a prohibited substance in Italy.
- Toxicity: The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific ...
- Dangerous with: Desomorphine, Dissociatives, Naloxone
- Overdose risk: Overdose on Methoxphenidine can range from unpleasant to life-threatening depending on the dose, ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 8 hrsHow It Feels
The onset is slow, measured, and offers little warning of the depth that follows. Forty-five minutes pass with only a subtle heaviness in the limbs and a faint dulling of ambient sound. You might adjust your position on the sofa and notice that the act of moving feels slightly more deliberate than usual, as though your body is responding on a quarter-second delay. An hour in, and the dissociation is unmistakably present but still gathering force, building with the slow inevitability of a weather front moving across a plain.
The come-up continues to deepen well past the first hour, and confusion arrives alongside the dissociation like an uninvited twin. This is Methoxphenidine's defining quality: a cognitive opacity that thickens as the experience deepens, making thought itself feel labored and uncertain. You begin a sentence and find the end of it has wandered off somewhere. You look at a familiar object and know that you should recognize it but cannot quite locate the word or the meaning. Sound is muffled and strange, as though arriving from a great distance and through an unfamiliar medium. The body is numb and heavy, pinned to whatever surface you are lying on by a gravity that seems to have doubled.
At the peak, the confusion becomes the experience. You are not observing interesting dissociative phenomena from a point of detached clarity — you are simply confused, deeply and thoroughly, in a way that affects every level of cognition. Spatial reasoning collapses; the room may seem to have rearranged itself, or to extend in directions that should not exist. Time is profoundly disrupted — you have no idea whether five minutes or two hours have passed, and the question itself seems difficult to formulate. Closed-eye space is dark and disorganized: fragmented images, half-formed scenes that collapse on inspection. There is no euphoria to speak of, though the numbness itself is not unpleasant.
The duration is punishing — eight to twelve hours, with the confusion persisting long after the dissociation has begun to lift. The return to baseline is slow and marked by a heavy, hung-over feeling: thick-headed, slightly dizzy, and fundamentally tired. Memory of the experience is patchy at best; entire hours may be simply missing. Sleep, when it finally arrives, is deep but unrefreshing. The compound leaves behind a sense of having lost time rather than having spent it, as though you fell asleep in one place and woke up in another with no memory of the journey between.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(15)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Gait alteration— Gait alteration is a noticeable change in the way a person walks and moves through their environment...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical disconnection— A perceptual distancing from one's own physical body that ranges from a subtle sense of numbness or ...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(11)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(17)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Rejuvenation— A renewed sense of physical vitality, mental freshness, and emotional restoration that can emerge du...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Auditory(2)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(2)
- Memory replays— Memory replays are vivid, multisensory re-experiences of past events that go far beyond normal recal...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
MXP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”
Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.
It should be noted that like other diaryethylamines, methoxphenidine is reported to have a much more rapid onset and lower half-life when vaporized or smoked. When consumed this way, it is a suspected to be carcinogenic when excess heat is used. Some user reports have concluded that vaporization requires as low as 20% of what would be a common oral dose for that person.
The toxicity and long-exact toxic dosage is unknown. This is because MXP has very little history of human usage.
Anecdotal reports from those who have tried this substance that there do not seem to be any negative health effects attributed to simply trying it by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
As with other NMDA receptor antagonists,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with Cross-all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.
Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
=References=
Detection Methods
Standard Drug Panel Inclusion
Methoxphenidine (MXP, 2-MeO-diphenidine) is NOT included on standard drug screening panels. It does not cross-react with PCP or ketamine immunoassays. Standard 5-panel, 10-panel, and extended drug tests will not detect this compound.
Urine Detection
MXP is detectable in urine for approximately 2 to 5 days after a single dose. The compound is metabolized by O-demethylation and hydroxylation. Specific metabolic pathways have been partially characterized through in vitro and case report studies. The diarylethylamine structure (rather than arylcyclohexylamine) gives MXP distinct metabolic properties. LC-MS/MS methods specifically targeting MXP and its metabolites are required.
Blood and Serum Detection
Blood detection windows are approximately 1 to 3 days. Pharmacokinetic data comes from forensic case reports. Fatal cases have been documented, providing some blood concentration data. The relatively long duration of action (4 to 6 hours) suggests moderate metabolic stability.
Hair Follicle Detection
Hair analysis for MXP is feasible with LC-MS/MS methods but has not been widely validated. Expected detection windows are up to 90 days.
Confirmatory Methods
LC-MS/MS is required for definitive identification. The diarylethylamine structure produces mass spectral fragmentation patterns that are distinct from arylcyclohexylamine dissociatives. Reference standards are available from forensic chemistry suppliers.
Reagent Testing
The Marquis reagent may produce a faint yellow color. The Mandelin reagent may yield an orange to brown response. Reagent profiles are not well established and should not be relied upon for identification. Fentanyl test strips are recommended for any product from unregulated sources.
Interactions
| Substance | Status | Note |
|---|---|---|
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dissociatives | Dangerous | — |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCMo | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 25E-NBOH | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T-2 | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T-21 | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Methoxphenidine is an example of a designer drug, specifically chosen to mimic the functional or structural features of commonly used illicit substances and circumvent government regulation.
Methoxphenidine, or 2-MeO-Diphenidine, is a synthetic compound of the diarylethylamine class. Methoxphenidine's chemical structure contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. The terminal amino group of the phenethylamine chain is incorporated into a piperidine ring. Hence, methoxphenidine belongs to the piperidine dissociative class of compounds.
Methoxphenidine is a structural analog of diphenidine, featuring a methoxy group at the two position of a phenyl group.
MXP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”
Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.
It should be noted that like other diaryethylamines, methoxphenidine is reported to have a much more rapid onset and lower half-life when vaporized or smoked. When consumed this way, it is a suspected to be carcinogenic when excess heat is used. Some user reports have concluded that vaporization requires as low as 20% of what would be a common oral dose for that person.
The toxicity and long-exact toxic dosage is unknown. This is because MXP has very little history of human usage.
Anecdotal reports from those who have tried this substance that there do not seem to be any negative health effects attributed to simply trying it by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
As with other NMDA receptor antagonists,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with Cross-all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.
Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
Diphenidine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
=References=
Harm Reduction
As with other NMDA receptor antagonists,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with Cross-all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.
- Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
- China:** As of October 2015, methoxphenidine is a controlled substance in China.
- Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
- Italy:** Methoxphenidine is a prohibited substance in Italy.
- Sweden:** Methoxphenidine is a prohibited substance in Sweden.
- Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
- Turkey:** Methoxphenidine is a classed as d
Toxicity & Safety
The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXP has very little history of human usage.
Anecdotal reports from those who have tried this substance that there do not seem to be any negative health effects attributed to simply trying it by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Dependence and abuse potential
As with other NMDA receptor antagonists, the chronic use of MXP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of MXP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Depressants (e.g. 2M2B, alcohol, barbiturates, benzodiazepines, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another and at higher doses, can lead to a sudden, unexpected loss of consciousness along with dangerously depressed respiration. There is also an increased risk of vomiting while unconsciousness and dying from the resulting suffocation. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Stimulants (e.g. amphetamine, cocaine, methylphenidate, MDMA) - This combination can potentiate the anxiety-inducing, manic, delusional and disinhibiting effects of dissociatives, particularly those without pronounced motor suppressing components such as ketamine. The sum of these effects can increase the likelihood of an anxiety attack, delusions or a psychotic episode. There is also evidence that suggests that combining these two increases their neurotoxicity. Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.
Dissociatives (e.g. dextromethorphan, ketamine, methoxetamine, PCP) - Combination can unpredictably potentiate amnesia, sedation, motor control loss and delusions. It may also result in a sudden loss of consciousness along with a dangerous amount of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose on Methoxphenidine can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
=References=
Experience Reports (1)
Tips (8)
Test Methoxphenidine with appropriate reagent kits. Dissociative powders are frequently mislabeled or adulterated. A Mandelin reagent test helps distinguish between some common dissociatives. Always use fentanyl test strips as well.
Frequent use of Methoxphenidine can cause urinary tract and bladder damage. If you notice increased urinary frequency, urgency, pain, or blood in urine, stop using immediately. This damage can become permanent.
Weigh your dose of Methoxphenidine with a milligram scale. Dissociative dose-response curves are steep. The difference between a pleasant floaty experience and complete dissociation from reality can be 50mg or less.
Daily dissociative use, including methoxphenidine, can lead to tolerance that escalates rapidly. Users who transitioned from daily DXM use report similar compulsive patterns developing with this substance.
Methoxphenidine has a notably long onset time. Wait at least 90 minutes before considering a redose, as premature redosing is the most common cause of unexpectedly intense experiences.
Do not combine Methoxphenidine with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Community Discussions (1)
See Also
References (4)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- PubChem: Methoxphenidine
PubChem compound page for Methoxphenidine (CID: 67833251)
pubchem - Methoxphenidine - TripSit Factsheet
TripSit factsheet for Methoxphenidine
tripsit - Methoxphenidine - Wikipedia
Wikipedia article on Methoxphenidine
wikipedia